Pharmacyte Biotech Stock Price on September 26, 2024
| PMCB Stock | USD 1.75 0.04 2.34% |
Below is the normalized historical share price chart for PharmaCyte Biotech extending back to September 11, 2003. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of PharmaCyte Biotech stands at 1.75, as last reported on the 3rd of December, with the highest price reaching 1.79 and the lowest price hitting 1.69 during the day.
If you're considering investing in PharmaCyte Stock, it is important to understand the factors that can impact its price. PharmaCyte Biotech appears to be dangerous, given 3 months investment horizon. PharmaCyte Biotech maintains Sharpe Ratio (i.e., Efficiency) of 0.0705, which implies the firm had a 0.0705% return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for PharmaCyte Biotech, which you can use to evaluate the volatility of the company. Please evaluate PharmaCyte Biotech's Risk Adjusted Performance of 0.0527, semi deviation of 4.68, and Coefficient Of Variation of 1728.13 to confirm if our risk estimates are consistent with your expectations.
At present, PharmaCyte Biotech's Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Other Stockholder Equity is expected to grow to about 150.5 M, whereas Common Stock Total Equity is forecasted to decline to 173.71. . At present, PharmaCyte Biotech's Price To Sales Ratio is projected to increase significantly based on the last few years of reporting. The current year's Price Earnings Ratio is expected to grow to 63.90, whereas Price To Operating Cash Flows Ratio is forecasted to decline to (9.91). PharmaCyte Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 17th of September 2010 | 200 Day MA 1.9746 | 50 Day MA 1.7688 | Beta (0.20) |
PharmaCyte |
Sharpe Ratio = 0.0705
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | PMCB | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.21 actual daily | 46 54% of assets are more volatile |
Expected Return
| 0.37 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average PharmaCyte Biotech is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of PharmaCyte Biotech by adding it to a well-diversified portfolio.
Price Book 0.2817 | Book Value 6.182 | Enterprise Value -13.9 M | Enterprise Value Ebitda (12.02) | Shares Float 7.3 M |
Related Headline
Shattuck Labs Headline on 26th of September 2024
Disposition of 2290 shares by Abhinav Shukla of Shattuck Lab... by Abhinav Shukla
Filed transaction by Shattuck Labs Officer Chief Technical Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
PharmaCyte Biotech Valuation on September 26, 2024
It is possible to determine the worth of PharmaCyte Biotech on a given historical date. On September 26, 2024 PharmaCyte was worth 1.7 at the beginning of the trading date compared to the closed value of 1.8. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of PharmaCyte Biotech stock. Still, in general, we apply an absolute valuation method to find PharmaCyte Biotech's value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of PharmaCyte Biotech where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against PharmaCyte Biotech's related companies.
| Open | High | Low | Close | Volume | |
| 1.85 | 2.00 | 1.64 | 1.68 | 57,609 | |
09/26/2024 | 1.70 | 1.94 | 1.70 | 1.80 | 20,063 |
| 1.78 | 1.95 | 1.78 | 1.84 | 18,277 |
| Backtest PharmaCyte Biotech | | | PharmaCyte Biotech History | | | PharmaCyte Biotech Valuation | Previous | Next |
PharmaCyte Biotech Trading Date Momentum on September 26, 2024
| On September 27 2024 PharmaCyte Biotech was traded for 1.84 at the closing time. The top price for the day was 1.95 and the lowest listed price was 1.78 . The trading volume for the day was 18.3 K. The trading history from September 27, 2024 was a factor to the next trading day price jump. The trading delta at closing time against the next closing price was 2.22% . The trading delta at closing time against the current closing price is 1.67% . |
PharmaCyte Biotech Fundamentals Correlations and Trends
By evaluating PharmaCyte Biotech's financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among PharmaCyte Biotech's main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. PharmaCyte financial account trend analysis is a perfect complement when working with valuation or volatility modules.About PharmaCyte Biotech Stock history
PharmaCyte Biotech investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for PharmaCyte is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in PharmaCyte Biotech will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing PharmaCyte Biotech stock prices may prove useful in developing a viable investing in PharmaCyte Biotech
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 9.6 M | 9.1 M | |
| Net Loss | -4.9 M | -5.1 M |
PharmaCyte Biotech Stock Technical Analysis
PharmaCyte Biotech technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
PharmaCyte Biotech Period Price Range
Low | December 3, 2024
| High |
0.00 | 0.00 |
PharmaCyte Biotech cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
PharmaCyte Biotech December 3, 2024 Market Strength
Market strength indicators help investors to evaluate how PharmaCyte Biotech stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading PharmaCyte Biotech shares will generate the highest return on investment. By undertsting and applying PharmaCyte Biotech stock market strength indicators, traders can identify PharmaCyte Biotech entry and exit signals to maximize returns
PharmaCyte Biotech Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for PharmaCyte Biotech's price direction in advance. Along with the technical and fundamental analysis of PharmaCyte Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of PharmaCyte to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0527 | |||
| Jensen Alpha | 0.1816 | |||
| Total Risk Alpha | (0.48) | |||
| Sortino Ratio | 0.0341 | |||
| Treynor Ratio | 0.3067 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for PharmaCyte Stock analysis
When running PharmaCyte Biotech's price analysis, check to measure PharmaCyte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PharmaCyte Biotech is operating at the current time. Most of PharmaCyte Biotech's value examination focuses on studying past and present price action to predict the probability of PharmaCyte Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PharmaCyte Biotech's price. Additionally, you may evaluate how the addition of PharmaCyte Biotech to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |